Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MAGE-A3 peptide–HLA-A*0201 complex
- Molecular classification
- Peptide–MHC class I complex, Tumor antigen–MHC complex, Other (not a standalone receptor or enzyme)
01
Overview
The MAGE-A3 peptide–HLA-A*0201 complex is formed when a peptide epitope derived from the tumor antigen Melanoma-associated antigen 3 (typically residues 112–120, KVAELVHFL) is presented on the cell surface by the major histocompatibility complex class I molecule HLA-A*0201. This complex is recognized by specific T cell receptors (TCRs) on cytotoxic T lymphocytes, leading to immune-mediated killing of MAGE-A3–expressing tumor cells. The complex is a prominent target for TCR-based adoptive cell therapies and peptide vaccines in cancer treatment. However, off-target reactivity and cross-reactivity remain important clinical safety issues.
- Other names
- MAGE-A3/HLA-A2 complexMAGE-A3–HLA-A0201MAGE-A3–HLA-A*0201 peptide complexMAGE-A3:112–120 (KVAELVHFL)–HLA-A2Melanoma-associated antigen 3 peptide–HLA-A2 complex
02
Mechanism of action
Recognition and killing of MAGE-A3–expressing tumor cells by TCR-engineered T cells or endogenous cytotoxic T lymphocytes (CTLs), upon binding to the MAGE-A3/HLA-A*0201 complex
03
Biological functions
Immune response (CD8+ T cell activation)Antigen presentationTumor cell recognition
04
Disease associations
Cancer (primarily in melanoma, non-small cell lung cancer, and other solid tumors)
05
Safety considerations
On-target, off-tumor toxicity (due to MAGE-A3 expression in some normal tissues)Cross-reactivity with other antigens such as Titin or MAGE-A12, which can lead to severe adverse effects like cardiac toxicity
06
Interacting drugs
Engineered T cell therapies (TCR-T)
2 more in the full profile.
07
Biomarkers
MAGE-A3 expression in tumors (by immunohistochemistry or PCR)Presence of HLA-A*0201 allele in the patientCirculating tumor-specific T cells
Beyond the preview
Go deeper on MAGE-A3 peptide–HLA-A*0201 complex.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MAGE-A3 peptide–HLA-A*0201 complex.